New York Life Investment Management’s BridgeBio Pharma BBIO Stock Holding History

New York Life Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.17M	Sell	15,768 -1,565	-9%	-$110K	0.01%	661
2026 Q1	$1.29M	Buy	17,333 +6,572	+61%	+$476K	0.01%	621
2025 Q4	$823K	Sell	10,761 -1,521	-12%	-$99.8K	0.01%	647
2025 Q3	$638K	Sell	12,282 -419	-3%	-$20.4K	0.01%	739
2025 Q2	$548K	Buy	+12,701	New	+$462K	0.01%	752
2024 Q3	–	Sell	-13,116	Closed	-$332K	–	848
2024 Q2	$332K	Buy	13,116 +1,406	+12%	+$38.4K	﹤0.01%	818
2024 Q1	$362K	Sell	11,710 -9,280	-44%	-$316K	﹤0.01%	1167
2023 Q4	$847K	Sell	20,990 -450	-2%	-$13.5K	0.01%	698
2023 Q3	$565K	Sell	21,440 -3,417	-14%	-$97K	0.01%	749
2023 Q2	$428K	Sell	24,857 -2,046	-8%	-$30.8K	﹤0.01%	891
2023 Q1	$446K	Buy	+26,903	New	+$314K	0.01%	1140

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

New York Life Investment Management's BBIO Position: Q2 2026 in Review

New York Life Investment Management reduced its BridgeBio Pharma (BBIO) stake by 9% in Q2 2026, selling an estimated $110K and leaving 15,768 shares worth $1.17M. The position accounts for 0.01% of the portfolio, ranked #661.

New York Life Investment Management first reported a position in BBIO in Q1 2023 and has held it in 11 quarters since. The position peaked at $1.29M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

New York Life Investment Management held 15,768 shares of BridgeBio Pharma worth $1.17M as of Q2 2026.
New York Life Investment Management sold 1,565 BridgeBio Pharma shares in Q2 2026, an estimated $110K.
BridgeBio Pharma made up 0.01% of New York Life Investment Management's portfolio in Q2 2026, its #661 holding.
New York Life Investment Management first reported a position in BridgeBio Pharma in Q1 2023 and has held it in 11 quarters since.
New York Life Investment Management's BridgeBio Pharma position peaked at $1.29M in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on New York Life Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.